Dementia 2025_ Event Postponement
This is to inform that due to some circumstances beyond the organizer control, "3rd Edition of International Alzheimer's Disease & Dementia Conference" (Dementia 2025) June 05-07, 2025 | Hybrid Event has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at dementia@magnusconference.com or call + 1 (702) 988 2320.
Between 2000 and 2050, the United Nations predicts that the number of individuals living with dementia in developed nations will rise from 13.5 million to 36.7 million. In the United States, there are around 4 million people living with dementia. Alzheimer's disease is the most common form of dementia, accounting for 50% to 70% of all cases and over 100,000 deaths each year. Alzheimer's disease prevalence and incidence rise with age, seemingly doubling every 5 years after the age of 60 and due of the significant link between age and Alzheimer's disease, researchers believe that biological processes linked with ageing may play a role in the disease's development, but that genetic, psychological, and environmental risk factors modify the disease's age-specific rates.
- Recent Findings and Treatments
- Pharmacologic Approaches
Yong Xiao Wang
Albany Medical College, United States
Nazneen N Dewji
Cenna Biosciences Inc, United States
Bin Hu
University of Calgary, Canada
James S Maniscalco
Northwell Health Staten Island University Hospital, United States
Nicholas Kendrick
Kaiser Permanente Mid Atlantic Permanente Medical Group, United States
Alford Madeline
CESPU University, Portugal
Charikleia Karastamati
University of Pavia, ItalySubmit your abstract Today
Important Alert:
X
Title : Early clinical development of modified P8 for the treatment of alzheimer’s disease
Nazneen N Dewji, Cenna Biosciences Inc, United States
Title : Who cares for the carers
Jacqueline Tuppen, Cogs Club, United Kingdom
Title : Memory should be the primary endpoint in early AD
Matthias W Riepe, Ulm University, Germany
Title : Down’s syndrome (trisomy 21) and alzheimer disease: A common medical and scientific fight
London Jacqueline, Paris Diderot University, France
Title : Quality of life children with autism spectrum disorder
Zhenhuan Liu, Guangzhou University of Chinese Medicine, China
Title : Efficacy of transcranial photobiomodulation in mild cognitive impairment and early alzheimer’s Disease: A randomized controlled study
Hyelim Chun, St.Peter’s General Hospital, Korea, Republic of